从临床研究需求,Toward Ready-to-Use Clinical Data Services 到开箱即用的病理数据for Computational Pathology

PathTrove 提供什么What PathTrove provides

已可用Available

查阅资源,准备数据Look up resources, prepare data

浏览资源档案与论文分析,按指南从官方渠道获取数据,使用已覆盖任务的标签文件。Browse resource reports and paper analyses, get data from official channels by following the guides, and use label files for the tasks already covered.

获得You get资源与研究证据 · 指南与标签Resource and research evidence · guides and labels
DEMO 体验Demo

用实际需求查找数据Find data from your actual needs

描述疾病、研究目标、所需模态和标签条件,从资源报告中找出候选资源,并给出匹配依据。Describe the disease, research goal, required modalities and label conditions; candidate resources are found in the resource reports, with the reason for each match.

获得You get候选资源 · 推荐依据Candidate resources · reasons for each match
开发中In development

开展深度可行性研究Run in-depth feasibility studies

结合资源条件与论文先例,拆解研究任务、分析数据组合和缺口,推进从需求到实验数据的准备。Combine resource conditions with precedents from papers to break down research tasks, analyze data combinations and gaps, and move from a need to experiment-ready data.

获得You get研究方案 · 数据组合 · 缺口与下一步Study plan · data combination · gaps and next steps

355

个资源,均附报告与下载指南resources, each with a report and a download guide

30

个解剖部位anatomical sites

105

个资源已整理标签文件resources with organized label files

01 / 数据库覆盖与整理01 / Database coverage and curation

找到相关资源,也看清研究条件。Find relevant resources, and see their research conditions.

355 个数据资源:261 个数据集 · 67 个挑战赛 · 27 个基准。
检索与可行性研究都建立在这套数据库上。
355 data resources: 261 datasets · 67 challenges · 27 benchmarks.
Search and feasibility studies are built on this database.

30 个解剖部位都有数据,常见癌种之外也有专科部位All 30 anatomical sites have data, including specialist sites beyond the common cancers

同一资源可涉及多个解剖部位。A resource can be tagged with several sites.

102 · 81 · 77个资源:乳腺 · 肺 · 结直肠resources for breast · lung · colorectum
27个其他部位other sites
58个资源涉及罕见病resources involve rare diseases
102
81
77
56
56
48
38
36
35
35
33
31
24
22
21
21
21
18
16
14
12
11
11
9
8
7
6
5
4
3
乳腺Breast肺Lung结直肠Colorectum脑Brain肾Kidney前列腺Prostate肝Liver淋巴结Lymph node皮肤Skin膀胱Bladder胃Stomach宫颈Cervix骨Bone食管Esophagus血液Blood卵巢Ovary胰腺Pancreas肾上腺Adrenal gland心脏Heart子宫Uterus头颈Head and neck软组织Soft tissue胆管Bile duct眼Eye脾Spleen胸膜Pleura睾丸Testis甲状腺Thyroid胸腺Thymus胃肠道GI tract
≥ 30 个资源≥ 30 resources10–29 个资源10–29 resources< 10 个资源< 10 resources

沿着病人的诊疗时间线,从诊断到随访结局都能找到数据Along the patient timeline, data exists from diagnosis to follow-up outcomes

各节点单独统计资源数。Each node is a separate resource count.

诊断Diagnosis病理评估pathology
63
生物标志物 / 受体Biomarkers / receptors
29
分期Stage
变量variable
23
分级Grade
变量variable
治疗Treatment基线、围术期与治疗baseline, perioperative, therapy
21
治疗前 / 基线Pre-treatment / baseline
4
术中 / 围术期Intra- / perioperative
36
治疗信息Treatment
随访Follow-up治疗后与结局after treatment
53
治疗后 / 随访Post-treatment / follow-up
21
总生存 OSOverall survival
结局outcome
21
复发Recurrence / relapse
结局outcome

常规病理图像之外,还有哪些数据?Beyond routine pathology images, what other data is there?

同一资源可包含多种模态,粉色标签列出各类的代表性资源。A resource can contain several modalities. Pink tags show a representative resource for each.

H&E
268
特殊染色Special stains
55
IHC / mIHC
52
IF / mIF
29cell-niches · 1,168 名患者 · 4,429 个 TMA 组织芯cell-niches · 1,168 patients · 4,429 TMA cores
分子数据Molecular
20SurGen · 843 名患者 · 完全开放SurGen · 843 patients · fully open
空间转录组Spatial transcr.
13HEST-1k · 1,276 组配对样本HEST-1k · 1,276 paired samples
CODEX
4CODEX-HCC · 15 名患者 · 646 张图像CODEX-HCC · 15 patients · 646 images
138 个资源提供不同染色或模态图像之间的对应关系138 resources link images across stains or modalities
43302828
逐像素对齐Pixel-aligned同一病例的不同图像Different images of the same case部分区域对齐Partly aligned regions算法生成的配对图像Algorithm-generated pairs同一切片的多种标记 9Several markers on one section 9

数据能支持什么,逐项查清楚What the data can support, checked item by item

每个资源按统一字段记录,每项附来源原文。Every resource is recorded with the same fields, each quoting its source.

任务标签Task labels预测什么 · 如何定义 · 标注来源What is predicted · how it is defined · where labels come from
临床信息Clinical information治疗 · 随访 · 分期 · 人群Treatment · follow-up · stage · population
实验条件Experimental conditions中心 · 设备 · 质控 · 数据划分Centers · devices · quality control · data splits
使用条件Terms of use开放范围 · 访问方式 · 数据许可Openness · access route · license
图像来源Image origin
205140
新采集Newly acquired复用已有图像Reuse existing images
复用图像的资源可能与来源数据集包含相同病例,使用时需考虑数据重叠。A resource that reuses images may share cases with the dataset it came from, so overlap has to be considered when using both.
原始数据的开放程度How open the original data is
53.2%42.8%
完全开放Fully open部分开放Partially open未开放 4.0%Not open 4.0%

168 个资源含结构化临床信息168 resources have structured clinical information

239 个资源记录扫描设备信息239 resources record the scanner

02 / 报告、指南与标签02 / Reports, guides and labels

从读懂数据,到准备实验。From understanding the data to preparing experiments.

资源报告 · 355 份Resource reports · 355

逐项核对数据条件,
让资源可以比较、结论可以追溯。
Every data condition checked,
so resources can be compared and conclusions traced.

每个资源一份报告,按统一的 38 个字段记录图像、标签、临床信息、数据划分和获取条件。全部报告共 13,490 个条目,附 16,936 条来源原文。One report per resource, recording images, labels, clinical information, data splits and access with the same 38 fields. Together the reports hold 13,490 entries backed by 16,936 source quotes.

每条附来源原文Every entry quotes its source

来源包括论文、官方页面、文件清单与元数据文件。Sources include papers, official pages, file listings and metadata files.

来源不一致时两边都保留When sources disagree, both are kept

记录各来源的表述,并说明最终采用的信息及理由。The report records what each source says and explains which value it uses and why.

区分研究描述与实际文件Study descriptions are separated from the actual files

论文使用的队列与实际发布的文件逐项对照,标签和临床信息注明统计单位。The cohort a paper used is checked against the files actually released, and labels and clinical information state their unit of count.

示例 · CRC-MSI 资源报告摘录 Example · CRC-MSI resource report excerpt

CRC-MSI(官方名称 TCGA-CRC-DX):从结直肠癌 H&E 图像预测微卫星不稳定性(MSI)。CRC-MSI (official name TCGA-CRC-DX): predicting microsatellite instability (MSI) from colorectal cancer H&E images.

研究任务Task
由 H&E 图像块预测 MSIH / nonMSIH。Predict MSIH / nonMSIH from H&E tiles.
图像条件Image conditions
颜色归一化肿瘤图像块;512 × 512 像素,0.5 μm/像素。Color-normalized tumor tiles; 512 × 512 pixels at 0.5 μm/pixel.
官方划分Official split
TRAIN:281 名患者、19,557 个图像块。
TEST:142 名患者、32,361 个图像块。
训练集为平衡类别做了下采样,测试集没有,因此测试集图像块更多。
TRAIN: 281 patients, 19,557 tiles.
TEST: 142 patients, 32,361 tiles.
The training set was downsampled to balance the classes and the test set was not, so the test set has more tiles.
两种口径Two counts
论文记载 TCGA 子队列 426 例;公开压缩包清单识别出 423 个唯一患者条码。报告同时记录两者。The paper records 426 patients in the TCGA subcohort; the public archive listings contain 423 unique patient barcodes. The report records both.
临床信息Clinical information
论文附表只有年龄、性别、分期等队列汇总,没有逐患者临床表。The paper's supplementary tables give only cohort summaries such as age, sex and stage; there is no per-patient clinical table.
证据依据Evidence
Zenodo 3832231、官方 ZIP 文件清单、Echle 等(Gastroenterology,2020)及补充表。Zenodo 3832231, the official ZIP file listings, Echle et al. (Gastroenterology, 2020) and its supplementary tables.

03 / 深度可行性研究 · 案例03 / In-depth feasibility study · case

从研究需求,到可以开始实验的数据。From a research need to data you can start experimenting with.

以卵巢癌的药物敏感性为例:先查清公开数据能支持哪些任务,
再把其中一项的数据准备到可以直接使用。
Taking drug sensitivity in ovarian cancer as the example: first find which tasks public data can support,
then prepare the data for one of them until it is ready to use.

研究需求Research need

用病理图像预测卵巢癌患者对药物的反应,公开数据能支持哪些评估?Predicting how ovarian cancer patients respond to drugs from pathology images: which evaluations can public data support?

铂类化疗Platinum chemotherapy

敏感 / 难治Sensitive / refractory可做FeasiblePTRC-HGSOC · 158 名患者PTRC-HGSOC · 158 patients
新辅助化疗后的病理反应Pathological response after neoadjuvant chemotherapy并入预后评估Merged into prognosis与预后队列是同一批患者Same patients as the prognosis cohort

贝伐珠单抗Bevacizumab

本例This case疗效:有效 / 无效Response: effective / invalid可做FeasibleOvarian-Bev · 78 名患者Ovarian-Bev · 78 patients
CA-125 下降速率(KELIM)CA-125 decline rate (KELIM)公开数据拼不出Not possible with public data缺同一批患者的 CA-125 连续测量No serial CA-125 for the same patients

PARP 抑制剂PARP inhibitors

随机分组获益Benefit across randomized arms有数据,未公开Data exists, not publicAGO-TR1 · PAOLA-1
CA-125 反应CA-125 response公开数据拼不出Not possible with public data标签与切片不在同一来源Labels and slides come from different sources
影像反应Imaging response公开数据拼不出Not possible with public data影像未公开,最多 20 例Imaging not public; 20 patients at most
获得性耐药Acquired resistance公开数据拼不出Not possible with public data没有用药期间的组织样本No tissue sampled during treatment
可做 2Feasible 2并入其他环节 1Merged elsewhere 1有数据未公开 1Data exists, not public 1公开数据拼不出 4Not possible with public data 4
1

论文报告:把“药物敏感性”拆成 8 项可以评估的任务。Paper reports: break “drug sensitivity” into 8 tasks that can be evaluated.

用到的资料:论文报告Material used: paper reports

药物、疗效终点或所需标签不同,就是不同的任务(上图)。每项写明需要什么数据,并找到已有先例。A different drug, response endpoint or required label makes a different task (see above). Each task states the data it needs, and existing precedents were found.

贝伐珠单抗疗效需要什么What bevacizumab response needs

CA-125 + 影像CA-125 + imaging

治疗前后的 CA-125 与 6 个月影像,由数据发布方判定有效或无效。CA-125 before and after treatment plus imaging at 6 months, judged effective or invalid by the data publisher.

同一终点的先例Precedent on the same endpoint

69.79%

UNI + VarMIL,患者级 balanced accuracy;测试集只有约 23–25 名患者。UNI + VarMIL, patient-level balanced accuracy; the test set had only about 23–25 patients.

决定:以贝伐珠单抗疗效为评估任务,按患者报告结果;测试集规模是首要限制。Decision: use bevacizumab response as the evaluation task and report results per patient; test-set size is the main limitation.
2

数据库:找到候选,查清每个资源能承担什么。Database: find candidates and check what each resource can do.

用到的资料:数据库表格、资源报告、数据源报告Material used: database tables, resource reports, data-source reports
初筛Screening

器官含卵巢的对象Objects whose organ includes ovary

49 个49

35 个来自资源报告,14 个来自数据源报告。35 from resource reports, 14 from data-source reports.

主要候选Main candidates

有药物疗效标签With drug-response labels

  • PTRC-HGSOC铂类 · 158 人PTRC-HGSOCplatinum · 158 patients
  • Ovarian-Bev贝伐 · 78 人Ovarian-Bevbevacizumab · 78 patients
  • ATEC23贝伐 · 180 个组织芯片点ATEC23bevacizumab · 180 TMA cores
本例选用Chosen for this case

Ovarian-Bev

78 人 / 286 张78 patients / 286 slides

有效 160、无效 126;有患者编号,可按患者划分。ATEC23 与它来自同一组织库,不能作独立外部验证。Effective 160, invalid 126; patient IDs allow patient-level splits. ATEC23 comes from the same tissue bank, so it cannot serve as independent external validation.

决定:Ovarian-Bev 只作评估;铂类与贝伐的疗效终点不同,结果分开报告,不合并。Decision: Ovarian-Bev is used for evaluation only; platinum and bevacizumab have different response endpoints, so their results are reported separately, not combined.
3

外部检索:确认缺口是真缺口,不是漏检。External search: confirm the gaps are real, not missed.

用到的资料:GEO、TCIA、GDC、Zenodo 等 26 个外部平台Material used: 26 external platforms, including GEO, TCIA, GDC and Zenodo
贝伐 KELIMBevacizumab KELIM

数据在别处,不在同一批患者The data exists elsewhere, for other patients

前 100 天的 CA-125 连续测量只见于其他研究,与切片不在同一批患者。Serial CA-125 from the first 100 days appears only in other studies, not for the patients with slides.

PARP 抑制剂PARP inhibitors

有数据,但不公开The data exists but is not public

AGO-TR1(208 人)与 PAOLA-1(447 人)有切片、随机分组和无进展生存,受许可限制不能公开下载。AGO-TR1 (208 patients) and PAOLA-1 (447 patients) have slides, randomized arms and progression-free survival, but licensing prevents public download.

铂类Platinum

找不到独立外部验证No independent external validation

TCGA-OV 的公开临床表没有末次铂类用药日期;改用 4 个中心之间的留一中心验证。The public TCGA-OV clinical table has no date of the last platinum dose; leave-one-center-out validation across 4 centers is used instead.

4

下载指南与划分 JSON:准备到可以开始实验。Download guide and split JSON: ready to start experiments.

用到的资料:下载指南、标签文件Material used: download guides, label files

对照官方切片清单,给每张切片补上患者编号并按患者划分;存在疑问的 21 张单列,暂不纳入。Each slide was matched against the official slide manifest, given a patient ID and split by patient; 21 slides with open questions are listed separately and left out for now.

按患者划分Split by patient73 名患者73 patients
511111
对应切片Matching slides265 张265 slides
2173117
训练Train验证Validation测试Test

同一患者不跨集合。划分为示例设计,不是官方划分。No patient appears in more than one set. The split is an example design, not an official split.

prepared.label.json 一条记录one record
{
  "sample_id": "1612595C.svs",
  "patient_id": "2909711",
  "split": "train",
  "label": {
    "bevacizumab_treatment_effectiveness": {
      "class_name": "effective", "class_id": 0
    }
  }
}